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1.  ABBREVIATIONS 
 
-/-   Null mutant / knock-out mouse 
AHR   Airway hyperresponsiveness 
Akt1   Ser/Thr protein kinase 
B220   CD45 
BAL   Bronchoalveolar lavage 
BALF   Bronchoalveolar lavage fluid 
Balb/c   Inbred Balb/c mice 
BRP-39   Breast regression protein-39 
BSA   Bovine serum albumin 
CC10   Clara cell 10kDa protein  
C57BL/6  Inbred C57 black 6 mice 
GP38K   38-kDa heparin-binding glycoprotein 
CD   Cluster of differentiation  
D-PAS  Diastase-periodic acid-Schiff 
Eos   Eosinophil granulocytes 
ELISA  Enzyme-linked immunosorbent assay 
FACS   Fluorescence-activated cell sorter 
Fas   Fas receptor, CD95 
Fc   Fragment crystallizable 
FCS   Foetal calf serum 
FITC   Fluorescein isothiocyanate 
FSC   Forward scatter 
HcGP-39  Human cartilage glycoprotein-39  
H&E   Hematoxylin and Eosin 
ICH   Immunhistochemistry 
IgG   Immunoglobuline G 
IgE   Immunoglobuline E 
IL-   Interleukin- 
kDa   Kilodalton 
mAb   Monoclonal antibody 
mDC   Myeloid dentritic cells 
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MFI   Mean fluorescence intensity 
MHCII  Major histocompatibility complex Class II 
MMR   Macrophage Mannose Receptor 
mRNA   Messenger ribonucleic acid 
OVA   Ovalbumin 
PBS   Phosphate-buffered-saline 
PI   Propidium iodide 
PMA   Phorbol myristate acetate 
r   Recombinant 
RNA   Ribonucleic acid 
RPMI   Roswell Park Memorial Institute medium  
RT   Room temperature 
rtTA   Reverse tetracycline transactivator 
RT-PCR  Reverse Transcriptase Polymerase Chain Reaction 
SSC   Side scatter 
SEM   Standard error of the mean 
SNP   Single-nucleotide polymorphism 
TGF-β1  Transforming growth factor beta 1 
Th2    T-helper cell type 2 
Tg   Transgenic 
w/v   Weight/volume 
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2.  INTRODUCTION 
2.1 Allergic Asthma  
Asthma is the most frequent chronic lung disease in children and has become the most common 
chronic disease in childhood within the last 30 years 3,4,42. Asthma is characterized by dry cough, 
wheezing and exercised-induced dyspnoea. Without early diagnosis and specific treatment, asthma 
results in loss of lung function, impaired quality of life and the risk to die from uncontrolled 
asthmatic attacks 47. Therefore, early diagnosis and specific treatment are required.  
Asthma is an atopic disorder and its occurence is mostly associated with a positive family 
history of allergic diseases 4. The immune response of allergic asthma is similar to the immune 
response that is seen in parasitic infections. Both diseases are characterized by a T-helper cell type 
2 (Th2) immune response 4,35. Whereas the Th2 immune response in parasitic infections has a 
physiologic role for anti-parasitic host defense, the overwhelming Th2 immune response in allergic 
asthma causes harm to the patient suffering from asthma without any evident beneficial 
physiologic role. The precise source of the dysregulated Th2 immune response in allergic asthma 
has not been elucidated as yet 11. Thus, several lines of research aim to identify key players in the 
pathogenesis of allergic asthma in order to design specific treatment strategies. 
 
2.2 Chitinases and chitinase-like proteins 
Chitinases and chitinase-like proteins are members of the evolutionarily conserved 18-glycosyl-
hydrolase family, which contains molecules which are true chitinases and molecules that lack 
chitinase activity. Much of the research in this area has focused on chitinases like acidic 
mammalian chitinase which are now known to play critical roles in the life cycle of many parasitic 
pathogens and the pathogenesis of Th2 and anti-parasite responses 12. However, the majority of the 
18-glycosyl-hydrolase family members are chitinase-like proteins which, as a result of mutations 
in their highly conserved enzyme sites, do not contain chitinase activity. Enzymatically active 
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chitinases include acidic mammalian chitinase and chitotriosidase in humans 2. Chitinase-like 
proteins include breast regression protein-39 (BRP-39) in the murine system, chitinase-like protein 
human cartilage glyocoprotein-39 (HcGP-39 / YKL-40), porcine 38-kd heparin-binding 
glycoprotein (GP38K), and bovine 39-kd whey protein. 
 
2.3 Chitinases and Chitinases-like Proteins in Allergic Asthma  
Mammalian chitinase-like proteins (as prototypical example BRP-39) are induced at sites of 
inflammation, parasitic infections 5 and tissue remodelling 23 . Thus these proteins are believed to 
play active roles in antiparasite defense and tissue repair responses. While it is believed that 
mammalian enzymes with true chitinase activity (as prototypical examples acidic mammalian 
chitinase and chitotriosidase) play a direct role in host responses to chitin-containing pathogens, it 
is also reasonable that chitinase-like proteins primarily modulate tissue inflammation, immunity 
and/or remodelling 12 . Host immune responses to parasites include an early innate component to 
control or eliminate parasitic infestation and an adaptive response which is antigen-specific. The 
immune response to parasites is frequently Th2 dominated and similar to tissue allergy. Both show 
an increased production of IL-4, IL-5, IL-13 and IgE and tissue eosinophilia. The Th2 
inflammatory response is originally generated to deal with parasites and other pathogens. Based on 
these notions, it is believed that allergy, atopic asthma and the inflammatory and remodeling 
responses are triggered in a parasite pathogen-independent fashion. These disorders occur when 
Th2 responses are poorly controlled 2,20. As chitinases and chitinase-like proteins are believed to 
play a key role in the innate immunity to parasites and other infectious agents, it is reasonable to 
hypothesize that, when produced in a dysregulated fashion, they also play an important role in the 
pathogenesis of allergy and/or asthma.  
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The role of acidic mammalian chitinase in murine asthma 
To test the hypothesis that chitinases are induced during and play essential roles in Th2 tissue 
responses, mRNA, protein and bioassay evaluation techniques have been used to assess the 
expression of acidic mammalian chitinase in lungs from mice with antigen-induced Th2 
inflammatory responses and transgenic mice in which IL-13 was overexpressed in a lung-specific 
fashion. These studies demonstrated that acidic mammalian chitinase mRNA and protein are 
prominently induced in epithelial cells and macrophages in these murine modeling systems 54. 
They also demonstrated that this induction was Th2 specific and that IL-13 was necessary for 
acidic mammalian chitinase induction in the mouse lung 54. This inductive event appeared to play 
an important role in Th2 inflammation because acidic mammalian chitinase-based interventions 
with anti-acidic mammalian chitinase antiserum or allosamidin decreased bronchoalveolar lavage, 
tissue inflammation and airways hyperresponsiveness. These findings suggest that acidic 
mammalian chitinase plays a critical role in allergic asthma. The functional role of BRP-39 in 
asthma, however, remains to be elucidated. 
 
YKL-40 in human asthma 
YKL-40 is the human homologous protein of murine BRP-39. Elevated levels of YKL-40 are 
found in a variety of human inflammatory diseases 23-26,38. Nevertheless, their role in allergic 
inflammation has not been addressed so far. Recent studies from our laboratory demonstrated that 
the levels of circulating YKL-40 are increased in patients with allergic asthma and correlate 
directly with asthma severity, airway remodeling and airway YKL-40 expression and inversely 
with lung function 10. Further studies revealed that single-nucleotide polymorphisms (SNPs) in the 
YKL-40 gene affect YKL-40 levels, asthma susceptibility and bronchial hyperresponsiveness 39. 
These findings demonstrated that YKL-40 might represent a novel biomarker that can be used to 
stratify asthmatics on the basis of disease severity and/or airway remodeling. The underlying 
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mechanism(s) by which YKL-40 modulates the pathogenesis of allergic asthma is unknown so far 
but is a prerequisite for considering YKL-40 as future therapeutic target. 
 
3. AIMS 
Previous studies suggest that chitinases / chitinase-like proteins may play a crucial role in allergic 
inflammation in mice and men. Recent studies highlight the role of YKL-40 as potential biomarker 
in allergic asthma in humans. However, the functional roles of chitinases/chitinase-like proteins, in 
particular BRP-39, are almost completely unknown. This is due, in part, to the fact that mice with 
null mutations of chitinase-like proteins have not been generated. Therefore, the aim of this study 
was to define the biology and functional involvement of the chitinase-like protein BRP-39 in 
allergic asthma. We had the following specific aims in this study: 
• Does the genetic deletion of BRP-39 in mice have an effect on ovalbumin-induced airway 
inflammation or Th2 inflammation in IL-13 overexpressing mice? 
• If so, which cells and soluble proteins are affected by the genetic deletion of BRP-39? 
• If so, what are the underlying mechansisms by which BRP-39 regulates allergic airway 
inflammation? 
Materignosis and 
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4. MATERIALS AND METHODS 
 
4.1 IL-13 Overexpressing Mice  
C57BL/6 and Balb/c wild-type inbred mice were obtained from the Jackson Labs (Bar Harbor, 
ME, USA). CC10-rtTA-IL-13 transgenic mice were previously generated and characterized in 
our laboratory (161), bred onto a C57BL/6 background and used in these studies. These mice 
utilize the Clara cell 10 kDa protein (CC10) promoter and the reverse tetracycline transactivator 
(rtTA) to target IL-13 to the lung in a doxycycline inducible manner. 
 
4.2 Generation of BRP-39-/- Mice 
BRP-39 null mutant mice were generated as described in Figure 1 and used to define the specific 
role of BRP-39 in vivo. Standard gene targeting approaches and homologous recombination were 
used to generate BRP-39 null embryonic stem cells and BRP-39-/- knockout mice. The targeting 
vectors that were used eliminated exons 1 to 6 and a part of the BRP-39 promoter (see Figure 1). 
Western, Southern and mRNA evaluations demonstrated the success of this approach. These mice 
were generated on a mixed 129/C57BL/6 background and were thereafter consequently bred for 
over 10 generations onto a C57BL/6 inbred strain mouse background. At baseline the BRP-39-/- 
mice were viable and fertile and were not able to be differentiated from the wild-type controls 
based on size, physical appearance, rate of growth or level of physical activity. In addition, 
autopsy, light microscopic examinations of skin and visceral organs, pulmonary compliance 
assessments and H&E, trichrome and elastin evaluations showed no differences between wild-type 
and BRP-39-/- animals (data not shown).  
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Figure 1. Generation of BRP-39 null mutant mice.  
Figure A depicts the constructs to genetically target the promoter and exons 1-6 of BRP-39. Figure B 
shows the genotyping control using specific primers and conventional PCR (DNA). Figure C shows the 
confirmation of BRP-39 knock-out on mRNA expression using RT-PCR and Figure D on protein levels 
using Western blotting. 
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4.3 OVA Sensitization and Challenge 
Six to eight week old BRP-39 null mutant mice and control littermates received i.p. injections 
containing 20μg of chicken OVA (Sigma, St. Louis, MO) complexed to alumn (Resorptar, 
Indergen, New York, NY) or alumn alone. This process was repeated 5 days later. After an 
additional seven days, the animals received three aerosol challenges (40 min a day, 3 consecutive 
days) with 1% OVA (w/v) in endotoxin-free PBS or PBS alone. The aerosol was generated in a 
NE-U07 ultrasonic nebulizer (Omron Health care, Vernon Hills, IL). The mice were sacrificed 24, 
48 or 72 h after aerosol exposure. In experiments in which the role of BRP-39 was being defined, 
OVA sensitization and boosting were undertaken as described above. Where indicated, aerosol 
OVA challenge was then undertaken in the presence and absence of an anti-BRP-39 antibody 
(engineered by Medimmune Inc.). In these experiments, the mice received 500μl doses of a rabbit 
polyclonal anti-BRP-39 or pre-immune serum controls via an intraperitoneal route, every other day 
starting the day before the aerosol challenge. 
 
4.4 BAL and Lung Inflammation 
Lung inflammation was assessed by BAL as described previously 49. Animals were anesthetized, a 
median sternotomy was performed, the trachea was dissected free from the underlying soft tissues 
and BAL was performed by perfusing the lungs in situ with 0.8 ml of PBS and gently aspirating 
the fluid back. This was repeated twice. The samples were then pooled and centrifuged and cell 
numbers and differentials were assessed. Cell pellets were further used for flow cytometric 
analyses and other experimental procedures. The cell-free BAL fluid was stored at –70 °C until 
used. 
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4.5 Histologic Analysis 
The lungs were removed en bloc, inflated at 25 cm pressure with PBS containing 0.5% low 
melting point agarose gel, fixed in Streck solution (Streck Laboratories, La Vista, NE), embedded 
in paraffin, sectioned and stained. Hematoxylin and Eosin and diastase-periodic acid–Schiff (D-
PAS) or MalloryTrichrome stains were performed in the Research Histology Laboratory of the 
Department of Pathology at the Yale University School of Medicine.  
 
4.6 Immunohistochemistry 
Immunohistochemistry (ICH) of BRP-39 was performed, using polyclonal rabbit anti-BRP-39 as 
the primary antibody 52. The antibody was applied to the lung sections at a 1/100 dilution. The 
specificity of the antibody was tested using the tissue samples from BRP-39 null mutant mice as a 
negative control.  
 
4.7 Immunoblot Analysis 
BAL (35 μl out of 2ml BAL fluid) and lung lysate (50μg) were subjected to immunoblot analysis 
using a polycclonal rabbit antiserum against BRP-39. BAL fluid protein or lung lysates were 
fractionated by SDS-PAGE, transferred to membrane and evaluated 27. 
 
4.8 Quantification of BRP-39 
The protein concentration of mouse BRP-39 was measured by ELISA according to the protocol 
provided by the manufacturer’s instructions with modifications. The levels of BRP-39 in BAL or 
lung lysates were evaluated by ELISA. In these experiments we used the anti-BRP-39 rabbit 
polyclonal IgG to capture and biotinylated anti-BRP-39 followed by horseradish peroxidase 
labeled streptavidin (Amersham, GE Healthcare, Piscataway, NJ) for detection. This assay detects 
as little as 50 pg/ml rBRP-39. This was undertaken with the assay noted above and confirmed with 
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a commercial assay (Quidel Inc. San Diego, CA). The absence of cross reactivity with other 
chitnase family members (acidic mammalian chitinase and chitotriosidase) was confirmed using 
concentrations of purified recombinant proteins upto a concentration of 100 ng/ml. 
 
4.9 mRNA Analysis 
mRNA levels were assessed using real-time RT-PCR assays as described previously in detail by 
our laboratories 33,36. In these assays, total cellular RNA from the lungs were obtained using 
TRIzol reagent (Invitrogen) according to the manufacturer's instructions. The sequences for the 
primers used in real-time RT-PCR were obtained from PrimerBank online 
(http://pga.mgh.harvard.edu/primerbank). 
 
4.10 Flow Cytometry 
Whole lung cell suspensions were obtained by a modified method according to Rice WR et al. 44. 
In brief, lung tissue was digested using dispase (Stem Cell technologies, 5 mg/ml), collagenase 
(0.04%; Sigma) and 100U/ml DNAse (Sigma). Both whole lung suspension cells and BAL cells 
underwent several centrifugations (10 min., 300g-1000g) and hemolysis (precooled hemolysis 
solution containing 11 mM KHCO3, 152 mM NH4Cl; washing 5 min, 400g at 4°C), were then 
strained through progressively smaller cell strainers (100-20 µM) and nylon gauze and were finally 
resuspended in FACS buffer (PBS, 2% BSA, 2% FCS) supplemented with 10 U/ml DNase1. For 
intracellular cytokine staining, cells were stimulated with PMA (50 ng/ml) / ionomycin (500 
ng/ml) (Merck) in RPMI 1640 in the presence of Brefeldin A (2µM, Sigma) for 6 h at 37°C before 
extracellular staining. For cell surface staining, the cells were incubated for 30 minutes at room 
temperature with purified rat anti-mouse CD16/CD32 mAb (1µg/105 cells; mouse Fc-Block; BD 
Biosciences) to prevent non-specific binding of antibodies to Fc receptors. Afterwards, cells were 
treated for 30 minutes at 4°C with appropriate combinations of specific antibodies for surface 
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marker staining, namely CD3, CD4, CD8, CD19, CD16, Siglec-F, CCR3, MHCII, CD80, CD86, 
CD40, CD11b, CD11c, B220, PDCA1, CD206 (MMR) and CD95 (Fas) to characterize specific 
cell types and analyze their receptors. The corresponding isotype controls were stained in parallel. 
Gating of leukocyte subtypes was based on light scatter properties and positive expression for 
characteristic surface markers as described in the respective figures. Propidium iodide (PI, 5 
μg/ml; Sigma) and Annexin V-FITC (5 μg/ml; BD Biosciences) were used to detect apoptotic 
(Annexin V+, PI-) and necrotic (Annexin V+, PI+) leukocytes. For intracellular staining, cells were 
fixed with 0.5 ml of ice-cold 2% paraformaldehyde, were permeabilized using 0.5% saponin 
(Sigma) and stained with anti–IL-4, anti-IL-13, anti-active Caspase 3 or anti-phospho-Akt1 (S473, 
R&D Systems) or the appropriate isotype control. For anti-phospho-Akt1 a SAP permeabilization 
buffer (0.1% (w/v) saponin, 0.05% (w/v) NaH3 in Hanks´ Balanced Salt Solution) was used. For 
anti-active Caspase 3 or anti-phospho-Akt1 staining, the antibodies were incubated at RT for 60 
minutes with the respective cells. All antibodies and FACS reagents were from BD Biosciences 
except otherwise indicated. Saturating concentrations of the antibodies were used as determined by 
titration experiments prior to the study. At least 10,000 cells/ sample were analyzed. Isotype 
controls were subtracted from the respective specific antibody expression and the results are 
reported as mean fluorescence intensity (MFI). Calculations were performed with Cell Quest 
analysis software (BD Biosciences). All experiments were performed in triplicate. 
 
4.11 Alternative Macrophage Activation 
Alternative macrophage (M2) activation was assessed by using an arginase activity assay 
(Bioassays Inc) 40 and surface staining of CD206 (macrophage mannose receptor, MMR) 46. In 
brief, thioglycollate (3%) was injected via an intraperitoneal route and peritoneal macrophages 
were harvested after 5 days, were incubated in RPMI 1640 (plus 10% FCS) for 48h with or 
without rBRP-39 (10µg/ml) or IL-4 (5ng/ml). Afterwards, cells were lysed in 0.5% Triton-X 
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containing Protease Inhibitor Cocktail Tablets (Roche) before performing the arginase activity 
assay. CD206 surface expression was performed as described in detail in the flow cytometry 
section. 
 
4.12 Statistics  
All data was initially checked for normal/parametric distribution (Kolmogorov-Smirnov-Test). If 
parametric distribution was found, analysis of variance (ANOVA) was applied to screen for 
differences among at least three groups. To compare two individual groups, Student’s t-test was 
applied. If non-parametric distribution was found, the Kruskal-Wallis test was applied to screen for 
differences among at least three groups, followed by the Mann-Whitney U test (Wilcoxon rank-
sum test) to compare two individual groups. Statistical analyses were performed using Prism 4.0 
(Graph Pad Software) and STATA version 8.2 for Windows (STATA Corporation). 
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5. RESULTS 
 
5.1 Regulation of BRP-39 by Th2 Inflammation 
To define the expression of BRP-39 in mice with acute Th2 inflammation we compared the levels 
of BRP-39 mRNA and protein expression in lungs from wild-type mice sensitized and challenged 
with OVA and appropriate non-sensitized and/or non-challenged wild-type controls. The levels of 
BRP-39 mRNA and protein in lungs from the control mice were near or below the limits of 
detection in our assays. In contrast, the levels of BRP-39 protein were significantly increased after 
OVA-sensitization and challenge (Figure 2A). This was readily detected 24 hours after aerosol 
OVA exposure and persisted at all time points that were assessed. This induction was not seen in 
mice that received a saline aerosol after OVA sensitization or an OVA aerosol after saline 
sensitization. In BRP-39 knock-out mice, BRP-39 was not detectable (Figure 2A). In all wildtype 
mice, immunohistochemistry demonstrated that BRP-39 was induced predominantly in airway 
epithelial cells and alveolar macrophages (Figure 2B, arrows). This staining was appropriately 
specific because it was not present when the primary antibody was pre-incubated with BRP-39 
peptide and when the primary antibody was not used in the evaluation. When viewed in 
combination, these studies demonstrate that BRP-39 is induced by Th2 inflammation, 
predominantly in airway epithelial cells and alveolar macrophages. 
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A 
 
 
B  
 
Figure 2. OVA-induced BRP-39 expression in the murine lung. Figure A: Western blot analysis of BRP-39 protein 
expression in wild-type and BRP-39 knock-out mice challenged with PBS or OVA; Figure B: Immunohistochemistry 
of BRP-39 staining in lung tissues of PBS or OVA treated wildtype mice. Black arrow indicates airway epithelial 
cells, white arrow indicates alveolar macrophages. 
 
WT             BRP-39 -/- 
PBS     OVA PBS     OVA 
PBS OVA
BRP-39 
(BALF) 
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5.2 Role of BRP-39 in OVA-Induced Inflammation and Physiologic Dysregulation  
Next, we evaluated whether the inhibition of BRP-39, achieved by genetic knock-out or antibody 
blocking, has an effect on aeroallergen-induced Th2 inflammation in mice. In wild-type mice, 
OVA-sensitization and challenge caused an impressive increase in tissue and BAL total cell, 
eosinophil, lymphocyte and macrophage numbers. Each of these inductive events was at least 
partially BRP-39-dependent, because null mutations of BRP-39 caused a significant decrease in 
each of these parameters (Figure 3A). The changes in cellular BAL content were most impressive 
for eosinophils. Similar findings were observed in comparison of OVA-sensitized and challenged 
wild-type mice treated with an anti-BRP-39 antibody (Figure 3B). Further studies were undertaken 
to determine if BRP-39 played a role in Th2 cytokine response. In contrast to OVA-sensitized and 
challenged wild-type mice, comparable Th2 cytokine induction was not found in OVA-sensitized 
and challenged mice with null mutations of BRP-39, because in the BRP-39 knock-out mice BAL 
levels of the prototypic Th2 cytokines IL-13 and IL-5 were decreased by > 90% compared to wild-
type animals. IL-4 was decreased by 50% compared to wild-type animals (Figure 3C). These 
studies indicate that the absence of BRP-39 reduces Th2 inflammation. 
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Figure 3. Role of BRP-39 in Th2 inflammation. Figure A and B: Differential cell counts in wild-type, BRP-39-/- and 
anti-BRP-39 antibody treated wild-type mice in the OVA model. Figure C: Cytokine analysis in BAL of wild-type and 
BRP-39-/- mice in the OVA model. *p<0.05 
 
5.3 BRP-39 Regulation of Dendritic Cells and Alternative Macrophage Activation 
To understand the underlying mechanism by which BRP-39 regulates Th2 inflammation, we 
initially focussed on dendritic cells since dendritic cells are the central initiators and regulators of 
Th2 inflammation. In particular, myeloid dendritic cells (mDC) are well-known to play an 
essential role in the pathogenesis of pulmonary Th2 inflammation 31. Therefore, we analyzed the 
percentages of mDCs and the activation status of mDCs by means of CD86 and CD40 surface 
expression using flow cytometry. These experiments showed that the number of mDCs was 
increased in lungs from wild-type mice that had been sensitized and challenged with OVA 
compared to non-sensitized or non-challenged mice (Figure 4A). After OVA sensitization and 
WT/PBS 
BRP-/-/PBS 
WT/OVA 
BRP-39-/-/OVA 
Control IgG/PBS 
Anti-BRP-39/PBS 
Control IgG/OVA 
Anti-BRP-39/OVA 
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challenge, mDC showed increased levels of CD86 (Figure 4B) and CD40 (Figure 4C) surface 
expression compared to cells from PBS sensitized and/or challenged mice. BRP-39 played an 
important role in these responses because mDC accumulation and mDC expression of CD86 and 
CD 40 were significantly decreased in lungs from sensitized and challenged BRP-39-/- mice 
(Figure 4, A-C). These studies showed that BRP-39 stimulates the Th2-induced accumulation and 
activation of pulmonary mDCs. 
 
    
Figure 4. Role of BRP-39 in dendritic cell accumulation and activation. Myeloid dendritic cells (mDCs) in murine 
lungs were identified by coexpression of CD11c, MHCII and CD11b and negative expression of B220. mDC 
activation was analyzed by CD86 and CD40 expression. Figure A shows percentages of mDCs in wild-type and BRP-
39 KO mice with or without OVA sensitization and challenge. Figure B shows the surface expression of CD86 on 
murine pulmonary mDCs (MFI = mean fluorescence intensity). Figure C schows CD40 surface expression on mDCs. 
*p<0.05 
 
Another important mechanism in allergic inflammation is the conversion of macrophages towards 
alternative macrophage (M2) activation. To see if recombinant (r) BRP-39 contributed to the 
alternative activation of macrophages, we analyzed alternative macrophage activation in BALF 
measured by surface expression of the macrophage mannose receptor (MMR) on F4/80+ alveolar 
macrophages in wild-type and BRP-39 deficient mice. As shown in Figure 5, OVA sensitization 
and challenge resulted in an impressive upregulation of MMR surface expression (Figure 5A, left 
panel) on macrophages and an accumulation of MMR+ alveolar macrophages in the lungs from 
A B C 
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wild-type mice (Figure 5A, right panel). To investigate and confirm this mechanism in vitro, 
isolated peritoneal macrophages were harvested and incubated with PBS, rBRP-39 or IL-4 as 
positive control for M2 alternative macrophage activation. Alternative macrophage activation was 
measured by MMR surface expression on peritoneal macrophages (Figure 5B, left panel) and 
arginase 1 activity of lysed isolated peritoneal macrophages (Figure 5B, right panel). In these 
experiments rBRP-39 caused a significant increase in arginase 1 activity and an upregulation of 
MMR surface expression compared to PBS treatment. This alternative activation was found after 
48 hours of macrophage-BRP-39 incubation where it was almost comparable to the effects of the 
positive control IL-4. These studies demonstrate that BRP-39 induces alternative macrophage 
activation in vitro and suggest that the induction of alternative (M2) macrophage activation may 
represent a key underlying mechanism by which BRP-39 triggers Th2 airway inflammation in 
vivo. 
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B 
 
Figure 5. Decreased OVA-induced alternative alveolar macrophage activation in the absence of BRP-39. Figure 
5A shows alternative macrophage activation as measured by MMR surface expression on F4/80+ BAL macrophages. 
The left panel shows the surface expression of MMR (MFI) on F4/80+ BAL macrophages, the right panel the 
percentage of MMR+ alveolar macrophages in BALF. Where indicated, BRP-39 knock-out mice were used. Where 
indicated, the OVA sensitization and challenge model was performed. Figure 5B depicts the effect of recombinant 
BRP-39 (10 µg/ml) or IL-4 (5 ng/ml) on alternative macrophage activation as measured by arginase 1 activity of lysed 
on isolated peritoneal macrophages (left panel) or by MMR surface expression on isolated peritoneal macrophages 
(right panel). *p<0.05 
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5.4 BRP-39 Regulation of Inflammatory Cell Apoptosis 
In a further step, we compared the cell death responses, including apoptosis (programmed cell 
death) and necrosis, of inflammatory cells (macrophages, CD4+ lymphocytes and eosinophils) in 
OVA sensitized and challenged wild-type and BRP-39-/- mice to evaluate whether BRP-39 might 
play a role in inflammatory cell apoptosis. These studies detected enhanced levels of annexin V 
staining of lung and BAL CD4 cells, macrophages and eosinophils in BRP-39-/- mice compared to 
wild-type mice (Figure 6A). This included cells with enhanced levels of expression of annexin V 
only (apoptosis) and cells that stained with annexin V and propidium iodide (PI) (late apoptosis / 
mixed apoptosis and necrosis) (Figure 6B). This in vivo cell death response(s) was associated with 
enhanced CD95 (Fas) surface expression, a key receptor involved in the induction of leukocyte 
apoptosis (Figure 6C). When viewed in combination, these studies demonstrate that BRP-39 is an 
important inhibitor of eosinophil, T cell and macrophage death receptor-mediated apoptosis in 
vivo.  
 
 
A 
  
27 
 
 
 
B 
  
28 
 
 
Figure 6. Role of BRP-39 in inflammatory cell apoptosis. Figure 6A: Apoptosis was analyzed by Annexin V surface 
staining on CD4+ T cells, F4/80+ alveolar macrophages and eosinophils in BAL of wild-type and BRP-39 knock-out 
mice. Where indicated, the OVA sensitization and challenge model was performed as described in detail in the 
methods section. Figure 6B depicts representative FACS plots of Annexin V and propidium iodide staining of CD4+ T 
cells, F4/80+ alveolar macrophages and eosinophils. Figure 6C shows Fas (CD95) surface expression on CD4+ T cells, 
F4/80+ alveolar macrophages and eosinophils in BALF. *p<0.05 
 
 
5.5 BRP-39 and IL-13 
IL-13 is the major effector cytokine at sites of Th2 inflammation and a powerful regulator of 
chitinase expression. 54 Thus, studies were undertaken to determine if IL-13 also regulates BRP-39 
and the role of BRP-39 in the pathogenesis of IL-13-induced inflammation and tissue remodeling 
was defined. The levels of BRP-39 mRNA and protein were significantly higher in lungs from IL-
13 transgenic (Tg) mice compared to the wild-type controls (Figure 7A). BRP-39 was most 
prominent in airway epithelial cells and alveolar macrophages (Figure 7B). In the latter 
experiments, IL-13 Tg mice with wild-type and null BRP-39 loci were generated and the tissue 
effects of IL-13 in these animals were compared. IL-13 overexpression in the transgene murine 
lung caused an increase of inflammatory cell (CD4+ T cells and macrophage) apoptosis (Figure 
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7C). This induction of apoptosis was largely abrogated when BRP-39 was genetically knocked-
out. These studies demonstrate that BRP-39 is induced by IL-13 and plays a critical role in IL-13-
induced inflammatory cell apoptosis. 
 
A. 
  
 
B. 
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C. 
 
Figure 7. IL-13 induces BRP-39 expression and modulates IL-13-induced inflammatory cell apoptosis and 
airway remodeling. Figure A shows BRP-39 protein detection by Western blotting in BALF of wild-type and IL-13 
transgenic overexpressing mice. Figure B shows BRP-39 staining using immunohistochemistry in lung tissue sections 
from wild-type and IL-13 transgenic overexpressing mice. The black arrow indicates BRP-39+ alveolar epithelial 
cells, the white arrows show BRP-39+ alveolar macrophages. Figure C shows Annexin V surface staining in CD4+ T 
cells and F4/80+ alveolar macrophages of BALF from wild-type and IL-13 tg mice. *p<0.05 
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6.  DISCUSSION 
These studies demonstrate for the first time a role for the chitinase-like protein BRP-39 in Th2 
inflammation. Genetic knock-out studies and antibody blocking experiments substantiated the 
functional role of BRP-39 in the pathogenesis of Th2 inflammation in vivo. This effect was 
mediated by modulation of dendritic cells recruitment and activation, alternative macrophage 
activation and inflammatory cell apoptosis, possibly mediated via a Fas-dependent pathway. 
Together with data from human studies, these findings strongly suggest BRP-39 as novel 
pharmaceutical target in allergic asthma. 
 
6.1 BRP-39 
BRP-39 was initially discovered in mouse breast cancer cells 43. Subsequently, a variety of 
differentially termed homologues were described, including human YKL-40, human HcGP-39, 
porcine 38 kDa heparin-binding glycoprotein (GP38K), bovine 39 kDa whey protein and 
drosophila Imaginal Disc Growth Factors 17,28,41. In the breast, the expression of BRP-39 and 
bovine 39 kDa whey protein are increased during the extensive glandular remodeling that is seen 
in the involution phase after the cessation of lactation 43. In drosophila, BRP-39-like molecules that 
lack chitinase activity act as growth factors. In porcine systems, GP38K induces the differentiation 
of cultured vascular smooth muscle cells 28. Human YKL-40/HcGP-39 has been described to be 
produced by cultured chondrocytes and synovial cells, where it regulates cell proliferation and 
survival and has mitogenic effects on human skin and lung fibroblasts and synoviocytes 17,41. This 
limited body of information suggests that BRP-39/YKL-40 might play a role in tissue remodelling 
and cell survival. Because the levels of HcGP-39/YKL-40 are elevated in a variety of human 
diseases, it is also been thought to contribute to pathologic remodeling responses such as lung 
diseases 10,23,26,38,41. However, the biological roles of these BRP-39-like moieties in normal 
physiology and disease pathogenesis are poorly understood. In fact, our limited understanding of 
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the functions of these strongly conserved and therefore presumably biologically important moieties 
in mammals and man is believed to be one of the most pressing issues in chitinase/chitinase-like 
proteins biology 1. Therefore, we performed studies using in vitro and in vivo experimental 
approaches, to define the functional role of BRP-39 in animal models of Th2 inflammation. These 
studies indicated an essential role for BRP-39 in dendritic cell accumulation and activation, 
alternative macrophage activation and inflammatory cell apoptosis/survival, mechanism that have 
a broad biological relevance also beyond allergic asthma. Further studies are, however, necessary 
to evaluate the functional significance of BRP-39 in other inflammatory disease conditions. 
 
6.2 BRP-39 and Th2 inflammation 
To address BRP-39 and Th2 inflammation, we generated and characterized BRP-39 knock-out 
mice. These studies add to our understanding of the biology of chitinase-like proteins by 
demonstrating for the first time, that BRP-39 plays a critical role in the pathogenesis of Th2 
inflammation, Th2 cytokine production, dendritic cell accumulation and activation and IL-13-
induced inflammation and remodeling. These studies also provide insights into the mechanisms 
that may underlie these effects by demonstrating that BRP-39 is an important regulator of CD4+ T 
cell, macrophage and eosinophil apoptosis, CD95 (Fas) expression, dendritic cell accumulation 
and activation and alternative macrophage activation. BRP-39 seems to be involved in several 
steps of the allergic/Th2 immune response: accumulation and activation of antigen-presenting cells 
(dendritic cells), modulation of alveolar macrophages into alternatively activated (M2) 
macrophages and protecting recruited bronchoalveolar inflammatory cells (CD4+ T cells, pro-
inflammatory macrophage subsets and eosinophils) from apoptosis, thereby prolonging and 
enhancing the local airway inflammation. Our observation that genetic knock-out of BRP-39 
increased the surface expression levels of the pro-apoptotic mediator / death receptor Fas (CD95) 
suggested an involvement of Fas-ligand/Fas-mediated apoptosis in BRP-39-induced tissue 
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responses. Based on this notion, BRP-39 might have an anti-apoptotic role in vivo and loss of 
BRP-39 triggers apoptosis by upregulation of Fas surface expression. Whether the effect on Fas is 
a direct or indirect consequence of lack of BRP-39 can not be differentiated based on our data. 
Further studies are required to understand the underlying pathways by which BRP-39 modulates 
inflammatory cell apoptosis/survival, downstream of Fas. Nevertheless, it is easy to conceive how 
elevated levels of tissue and/or circulating BRP-39 can inhibit inflammatory cell death and 
augment the accumulation of T cells, alternatively activated macrophages and dendritic cells, 
thereby regulating the intensity and natural history of Th2-dominated diseases such as asthma. 
These findings also provide a potential mechanism via which BRP-39 can contribute to the 
severity and activity of diseases, such as rheumatoid arthritis, diabetes, inflammatory bowel 
disease, pulmonary fibrosis, sarcoidosis, atherosclerosis and other chronic inflammatory diseases, 
in which T cells and macrophages are believed to play important pathogenic roles. Asthmatic 
airways dysfunction used to be considered largely in terms of the contraction of airway smooth 
muscle (bronchospasm). However, numerous studies have suggested a renewed appreciation of the 
essential role of inflammation in this disorder. The central roles of Th2 cells needs to be accented 
because they are now believed to be major contributors to the initiation and maintenance of airway 
inflammation, regulation of B cell and eosinophil function, and induction of mucus and stimulation 
of airway remodeling 1,4,13,15. Previous studies from our laboratory demonstrated that the true 
chitinase acidic mammalian chitinase is induced by IL-13 and plays an important role in Th2 
inflammation. They also demonstrated that acidic mammalian chitinase is expressed in an 
exaggerated fashion in human asthma 54. The present studies add to our understanding of the 
relationships between 18 glycosyl hydrolase family members and Th2 inflammation by 
demonstrating that BRP-39 is induced during and plays a critical role in the pathogenesis of 
aeroallergen-induced Th2 responses. These observations suggest that a variety of chitinases and 
chitinase-like proteins contribute to the pathogenesis of Th2 inflammation. Because BRP-39 is not 
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a functional chitinase, they also suggest that their contributions in this setting may not be 
dependent on chitinase enzyme activity. Our demonstration that BRP-39 is a critical regulator of 
inflammatory cell apoptosis provides a chitinase-independent mechanism that may underlie this 
effect. This observation is in keeping with other studies that demonstrate the important roles that 
inflammatory cell (T cell, macrophage and eosinophil) apoptosis plays in the initiation, 
perpetuation and intensity of Th2 inflammatory responses 16,45. Additional investigation will be 
required to determine wether acidic mammalian chitinase regulates inflammatory cell apoptosis 
and if acidic mammalian chitinase and BRP-39 regulate Th2 inflammation via identical 
mechanisms. 
 IL-13 is a product of a gene on chromosome 5 at q31 that is produced by stimulated CD4+ 
Th2 cells 13,51. Studies from our laboratory and others have demonstrated that it has a variety of 
effects that are relevant to asthma and Th2 inflammation including the ability to induce IgE 
production, eosinophil, lymphocyte and macrophage-rich inflammation, mucus metaplasia, airway 
remodeling and airways hyperresponsiveness (AHR) on methacholine challenge 14,51. Exaggerated 
levels of IL-13 have also been seen in atopic and non-atopic asthma 21,22,30 and polymorphisms in 
the IL-13 promoter and coding region have been associated with asthma in study populations 19. 
As a result of these observations, dysregulated IL-13 production is now felt to be a cornerstone in 
the pathogenesis of Th2 inflammation and remodeling. IL-13 also plays an important role in the 
pathogenesis of type II granulomatous responses and the fibrosis in schistosomiasis, idiopathic 
pulmonary fibrosis, scleroderma and radiation fibrosis 7-9,18,37,48,50. In keeping with these important 
findings, a number of investigators have worked to define the mechanisms that IL-13 uses to 
generate its tissue effects. As a result, it is now known that among a myriad of involved proteins in 
particular chemokines and chemokine receptors, matrix metalloproteinases, TGF-β1 and IL-11 
contribute to the pathogenesis of pulmonary Th2 inflammation and remodeling 6,29,32,34,53. The 
present studies demonstrate that BRP-39 is induced by and plays an important role in the 
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pathogenesis of IL-13 induced airway inflammation. They also demonstrate that, in the absence of 
BRP-39, exaggerated levels of T cell and macrophage apoptosis are seen in lungs from IL-13 Tg 
mice and that BRP-39 induces alternative macrophage activation. This is the first demonstration 
that a chitinase-like protein contributes to pathogenesis of a Th2 cytokine effector response and 
alternative macrophage activation. These studies also raise the possibility that the effects of BRP-
39 in Th2 responses are mediated by its ability to induce the differentiation and augment the 
survival of alternatively activated macrophages. This is in keeping with the appreciation that these 
macrophages are a major source of fibrogenic TGF-β1 in the IL-13-treated lung (Elias et al. 
unpublished observation). Further studies are required to understand the complex relationship 
between BRP-39, IL-13, alternative macrophage activation and TGF-β1. 
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7. SUMMARY 
In summary, these studies demonstrate, using genetic knock-out and antibody blocking 
experiments in vivo, that the chitinase-like protein BRP-39 is potently and selectively induced in 
macrophages and epithelial cells in lungs with Th2- and IL-13-induced inflammation, as murine 
model of human allergic asthma. These studies also demonstrate that BRP-39 plays a critical role 
in the pathogenesis of aeroallergen-induced Th2 inflammation and IL-13-induced inflammation 
and remodeling. Lastly, they demonstrate that BRP-39 mediates these effects, at least in part, by 
inhibiting inflammatory cell apoptosis, inhibiting Fas/CD95 surface expression, regulating myeloid 
dendritic cell accumulation and activation and inducing the alternative activation of local alveolar 
macrophages. These studies support BRP-39 as a therapeutic target against which interventions 
can be directed to control asthma or other Th2 or macrophage-mediated pathologies.  
 
ZUSAMMENFASSUNG 
Diese Studien zeigen, dass das Chitinase-ähnliche Protein BRP-39 eine entscheidende Rolle in der 
Pathogenese einer Th2 Entzündung in der Lunge spielt. Wir fanden, dass BRP-39 von 
Makrophagen und Epithelzellen in Lungen mit Th2 Inflammation und IL-13-induzierter 
Inflammation exprimiert wird. Unter Verwendung von genetischen BRP-39 knock-out Mäusen 
fanden wir, dass BRP-39 eine kritische Rolle in der Pathogenese der allergisch induzierten Th2 
Inflammation und damit assoziierten pulmonalen Umbauprozessen spielt. BRP-39 vermittelt 
diesen Effekt über eine Hemmung der zellulären Apoptose, die Regulation von Fas/CD95 
Oberflächenexpression, die Regulation der Rekrutierung und Aktivierung pulmonaler myeloider 
dendritischer Zellen und der Differenzierung lokaler Alveolarmakrophagen zu alternativ-
aktivierten Makrophagen. Diese Studie unterstreicht die Rolle von BRP-39 als funktionelle 
Komponente und als therapeutisches Ziel bei Asthma bronchiale. 
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